MedPath

Dihydroergotamine Mesylate Nasal

Dihydroertotamine Mesylate Nasal Spray, 4 mg/mL

Approved
Approval ID

1ecb2311-eee3-4230-a019-a3496308cff1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 13, 2024

Manufacturers
FDA

Cipla USA Inc.

DUNS: 078719707

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dihydroergotamine Mesylate Nasal

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69097-503
Application NumberANDA212907
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dihydroergotamine Mesylate Nasal
Product Specifications
Route of AdministrationNASAL
Effective DateJanuary 24, 2024
FDA Product Classification

INGREDIENTS (5)

DIHYDROERGOTAMINE MESYLATEActive
Quantity: 4 mg in 1 mL
Code: 81AXN7R2QT
Classification: ACTIB
CAFFEINEInactive
Code: 3G6A5W338E
Classification: IACT
ANHYDROUS DEXTROSEInactive
Code: 5SL0G7R0OK
Classification: IACT
CARBON DIOXIDEInactive
Code: 142M471B3J
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.